Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2024 | Advancing CML treatment: novel drugs, personalized treatment strategies, and improving TFR

Elisabetta Abruzzese • 4 Sep 2024
SOHO 2024
Chronic Myeloid Leukemia Leukemia

Elisabetta Abruzzese, MD, PhD, S. Eugenio University Hospital, Rome, Italy, discusses the ongoing advancements in chronic myeloid leukemia (CML) treatment, emphasizing the introduction of new drugs. She highlights the need for personalized treatment strategies and the current challenge of improving treatment-free remission (TFR) rates. Dr Abruzzese also points out the importance of managing long-term treatment to minimize side effects. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Elisabetta Abruzzese

Treatment-free remission in Ph+ ALL without alloSCT: ongoing research 1:48
Treatment-free remission in Ph+ ALL without alloSCT: ongoing research
Elisabetta Abruzzese • 4 Sep 2025
Exploring TKI de-escalation strategies in CML: outcomes of downgrading therapy 1:33
Exploring TKI de-escalation strategies in CML: outcomes of downgrading therapy
Elisabetta Abruzzese • 4 Sep 2025
A CML Campus study assessing the transition from high-potency to low-potency inhibitors in CML 3:51
A CML Campus study assessing the transition from high-potency to low-potency inhibitors in CML
Elisabetta Abruzzese • 6 Dec 2024
The impact of ponatinib on conception and pregnancy outcomes in patients with CML 2:13
The impact of ponatinib on conception and pregnancy outcomes in patients with CML
Elisabetta Abruzzese • 6 Dec 2024

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals